Recent 8-K filings for AIBT
Highest-materiality recent filing
Aibotics signs exchange agreement to acquire Empulser for up to $22M in Series C preferred stock
- Aibotics entered an Oct. 2, 2026 exchange agreement to acquire 100% of Empulser Enterprises LLC; consideration is up to $22M in Series C Preferred Stock, 2,200,000 shares at $10.00.
- Earn-out over 36 months: 220,000 shares at closing plus 198,000 shares per each of 10 milestones tied to patent filings, flight testing, pilot programs, and $500,000 cumulative revenue.
-
Aibotics signs exchange agreement to acquire Empulser for up to $22M in Series C preferred stock
Aibotics entered an Oct. 2, 2026 exchange agreement to acquire 100% of Empulser Enterprises LLC; consideration is up to $22M in Series C Preferred Stock, 2,200,000 shares at $10.00.
-
Mycotopia exchanges 9.79M common shares for super voting preferred; Ehave gets 75% voting control
Ehave Inc. exchanged 9,793,754 common shares (≈67% of outstanding) for 1,000 Series A Super Voting Preferred shares.
-
Acquires patents for Phill Robot (AI massage robot) and Milky Way (smart breast-milk fridge) from Philon Labs.
-
Mycotopia to restate 2022 financial statements; $288K cash comp and warrant to CEO omitted
Unrecorded $288,000 cash compensation and a warrant for 5% of fully diluted shares granted to CEO.
-
Mycotopia Therapies, PSLY.com, and Ei.Ventures mutually terminate merger agreement
Parties agreed to terminate the Agreement and Plan of Merger dated May 17, 2022 on February 16, 2023.
-
Mycotopia enters merger with Ei.Ventures under PSLY.com; total deal value ~$383M
Mycotopia shareholders to receive 0.25 PSLY.com share per TPIA share, valued at >$23M.
-
Mycotopia Therapies appoints Benjamin Kaplan as CEO; $24k/mo consulting fee, 5% equity warrants
CEO appointment effective Jan 19, 2021; initial 36-month term with automatic 12-month renewal.
Materiality & sentiment trend
Max materiality 0.87 · Median 0.65 · Most common event other_material